drugset / Trial / NCT01068951

Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells

NCT01068951

Completed 20 enrolled Uppsala University Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

The main hypothesis of the investigators study is that the development of autoimmune diabetes may be halted att diagnosis by the immune modulatory properties of mesenchymal stem cells.

Timeline

Start
2010-06
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous